drugset / Trial / NCT05017584
ED90 of 0.75% Bupivacaine for Bilateral Tubal Ligation (BTL)
RandomizedParallel-groupDouble-blindSupportive care
Summary
The purpose of this study is to determine the dose of bupivacaine that provides effective pain management in 90% (ED90) of patients undergoing bilateral tubal ligation. This will guide anesthesiologists on the most effective dose to minimize intraoperative pain during this procedure. The goal is to make women as comfortable as possible when they undergo this procedure while also minimizing the amount of time they are required to remain in the hospital afterwards for monitoring.
Timeline
- Start
- 2023-01
- Primary completion
- 2024-01-01
- Completion
- 2024-01-01
Outcome
Outcome not reported
Stopped (Enrollment): “Study halted prematurely, prior to enrollment of first participant”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bupivacaine | Other / unclassified | 10.5 mg | Intrathecal |
| Subject | Bupivacaine | Other / unclassified | 12 mg | Intrathecal |
| Subject | Bupivacaine | Other / unclassified | 13.5 mg | Intrathecal |
| Subject | Bupivacaine | Other / unclassified | 15 mg | Intrathecal |
Indications
No indication recorded.